-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Invivyd, Inc. F/k/a Adagio Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 3, 2023 - (IVVD)
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Invivyd, Inc. F/k/a Adagio Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 3, 2023 - (IVVD)
New York, New York--(Newsfile Corp. - February 7, 2023) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ: IVVD).
Shareholders who purchased shares of IVVD during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
CONTACT US HERE:
This lawsuit is on behalf of all purchasers of Adagio common stock between November 29, 2021 and December 14, 2021, both dates inclusive.
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.
DEADLINE: April 3, 2023 Shareholders should not delay in registering for this class action. Register your information here:
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of IVVD during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 3, 2023. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770
To view the source version of this press release, please visit
New York, New York--(Newsfile Corp. - February 7, 2023) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ: IVVD).
纽约,纽约--(Newsfile Corp.-2023年2月7日)-格罗斯律师事务所证券诉讼律师事务所代表以下股东发布以下通知Invivyd,Inc.f/k/a Adagio治疗公司(纳斯达克:IVVD)。
Shareholders who purchased shares of IVVD during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
鼓励在所列类别期间购买IVVD股票的股东就可能任命首席原告一事与公司联系。被任命为首席原告不需要参与任何追偿。
CONTACT US HERE:
请在此处联系我们:
This lawsuit is on behalf of all purchasers of Adagio common stock between November 29, 2021 and December 14, 2021, both dates inclusive.
这起诉讼是代表2021年11月29日至2021年12月14日期间(包括首尾两天)购买Adagio普通股的所有买家。
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.
指控:起诉书称,在上课期间,被告发表了具有重大虚假和/或误导性的陈述和/或误导性陈述,和/或未能披露:(A)已发表的表位映射、结构研究和序列分析表明,被告用来声称针对新冠肺炎的研究性单抗治疗药物对奥密克戎有效的表位映射、结构研究和序列分析不充分、不可靠,也不足以声称抗癌药物对奥密克戎有效;(B)被告关于抗炎药物对奥密克戎有效的说法缺乏合理的事实依据;及(C)抗炎药物集团对奥密克戎变体的有效性是其针对先前变体的有效性的300多倍。
DEADLINE: April 3, 2023 Shareholders should not delay in registering for this class action. Register your information here:
截止日期:2023年4月3日股东不应拖延登记参加这起集体诉讼。在此处注册您的信息:
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of IVVD during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 3, 2023. There is no cost or obligation to you to participate in this case.
股东的下一步行动:一旦您登记为在上面列出的时间范围内购买IVVD股票的股东,您将被登记在投资组合监控软件中,以在案件的整个生命周期中为您提供状态更新。寻求成为主要原告的最后期限是2023年4月3日。参与此案对您没有任何成本或义务。
WHY GROSS LAW FIRM? The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
为什么是格罗斯律师事务所?格罗斯律师事务所是全国公认的集体诉讼律师事务所,我们的使命是保护所有因欺诈、欺诈和非法商业行为而蒙受损失的投资者的权利。格罗斯律师事务所致力于确保公司遵守负责任的商业实践,并从事良好的企业公民行为。当一家公司的虚假和/或误导性陈述或重大信息遗漏导致该公司股票人为膨胀时,该公司代表遭受损失的投资者寻求赔偿。律师广告。以前的结果并不能保证类似的结果。
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
格罗斯律师事务所致力于确保公司遵守负责任的商业实践,并从事良好的企业公民行为。当一家公司的虚假和/或误导性陈述或重大信息遗漏导致该公司股票人为膨胀时,该公司代表遭受损失的投资者寻求赔偿。律师广告。以前的结果并不能保证类似的结果。
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770
联系方式:
格罗斯律师事务所
西38街15号,12楼
纽约,纽约州,10018
电子邮件:dg@securitiesclasslaw.com
电话:(212)537-9430
传真:(833)862-7770
To view the source version of this press release, please visit
要查看本新闻稿的源版本,请访问
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧